Qualigen Therapeutics Q2 2025 Earnings Report

Qualigen Therapeutics EPS Results

• Actual EPS: -$1.00
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Qualigen Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Qualigen Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/14/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Qualigen Therapeutics (NASDAQ:QLGN) (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.

Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories. These products support the detection and quantification of biomarkers ranging from infectious disease antigens to tumor-associated proteins. Qualigen’s diagnostic portfolio is sold to reference laboratories, hospital systems and point-of-care facilities across North America, Europe and select markets in Asia.

Qualigen BioTherapeutics is focused on developing a pipeline of antibody-based and cell-based immunotherapies targeting both hematologic and solid tumors. Its preclinical programs include monoclonal antibodies directed against validated cancer antigens as well as engineered cell therapies designed to enhance tumor recognition and cytotoxicity. The company applies proprietary protein conjugation and high-throughput screening platforms to advance candidates from lead identification through IND-enabling studies.